Author

Paul Ioannidis

Observed name: Ioannidis, Paul

Observed institutions: La Trobe University, Olivia Newton-John Cancer Wellness & Research Centre, Olivia Newton-John Cancer Research Institute

ORCID: 0000-0002-1003-7478

Observed ORCID: 0000-0002-1003-7478

OpenAlex ID: A5077944762

Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity

2019 · Mercedes Dávalos-Salas, Magdalene K. Montgomery, et al. · Nature Communications · 63

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

2017 · Candani S. A. Tutuka, Miles C. Andrews, et al. · Molecular Cancer · 59

ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2017 · Anderly C. Chüeh, Janson W.T. Tse, et al. · Clinical Cancer Research · 54

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

2022 · Andrew J. Weickhardt, David K. Lau, et al. · BMC Cancer · 20

Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al. · Clinical Cancer Research · 2

Dual targeting of FGFR3 and the ERBB receptor family or AXL enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

2021 · David Lau, Margeaux Hodgson-Garms, et al. · Research Square · 1

Supplementary Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Figure Legends from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Table from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Table from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Figures from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Data from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Supplementary Figures from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

2023 · Anderly C. Chüeh, Janson W.T. Tse, et al.

Additional file 1: of PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

2017 · Tutuka, Candani, Andrews, Miles, et al. · Figshare

Abstract 4728: Histone deacetylase inhibitors induce apoptosis in multiple tumor types through induction of ATF3

2016 · Anderly C. Chueh, Janson Tse, et al. · Cancer Research

Works count: 22

Citation count: 199

H-index: 4

I10-index: 4